Thrive Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.51M Buy
1,255
+63
+5% +$64.4K 0.19% 59
2026
Q1
$1.1M Buy
1,192
+33
+3% +$33.5K 0.16% 68
2025
Q4
$1.25M Sell
1,159
-67
-5% -$64.1K 0.18% 60
2025
Q3
$936K Sell
1,226
-67
-5% -$49.9K 0.14% 83
2025
Q2
$1.01M Sell
1,293
-36
-3% -$28K 0.16% 72
2025
Q1
$1.1M Sell
1,329
-114
-8% -$94.9K 0.21% 54
2024
Q4
$1.11M Sell
1,443
-63
-4% -$52.2K 0.2% 57
2024
Q3
$1.33M Sell
1,506
-22
-1% -$19.8K 0.24% 47
2024
Q2
$1.38M Sell
1,528
-26
-2% -$20.8K 0.27% 45
2024
Q1
$1.21M Buy
1,554
+361
+30% +$257K 0.25% 50
2023
Q4
$696K Sell
1,193
-56
-4% -$32.7K 0.15% 82
2023
Q3
$671K Sell
1,249
-273
-18% -$141K 0.18% 78
2023
Q2
$714K Buy
1,522
+775
+104% +$325K 0.18% 77
2023
Q1
$256K Sell
747
-111
-13% -$37.4K 0.07% 141
2022
Q4
$314K Sell
858
-266
-24% -$94.3K 0.09% 129
2022
Q3
$363K Sell
1,124
-29
-3% -$9.19K 0.13% 100
2022
Q2
$374K Buy
1,153
+1
+0.1% +$300 0.13% 98
2022
Q1
$330K Buy
1,152
+77
+7% +$19.8K 0.1% 120
2021
Q4
$297K Buy
+1,075
New +$273K 0.1% 121

Other funds holding LLY

Thrive Wealth Management's LLY Position: Q2 2026 in Review

Thrive Wealth Management increased its Eli Lilly (LLY) stake by 5.3% in Q2 2026, buying an estimated $64.4K and bringing the position to 1,255 shares worth $1.51M. The position accounts for 0.19% of the portfolio, ranked #59.

Thrive Wealth Management first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 903 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Thrive Wealth Management held 1,255 shares of Eli Lilly worth $1.51M as of Q2 2026.
  • Thrive Wealth Management bought 63 Eli Lilly shares in Q2 2026, an estimated $64.4K.
  • Eli Lilly made up 0.19% of Thrive Wealth Management's portfolio in Q2 2026, its #59 holding.
  • Thrive Wealth Management first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 903 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Thrive Wealth Management's 13F filing for Q2 2026, filed 7 Jul 2026.